ClinicalTrials.gg
Status unknownNCT03464370STELLAUpdated Jul 20, 2018

Evaluation of Stress Sensitivity and Hyperemotivity in Epilepsy Compared to and a Group of Healthy Volunteers

An interventional study of Measure of emotional stressors in Epilepsy, sponsored by University Hospital, Toulouse. Status unknown at 1 site in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-20.

Primary conditionEpilepsy, Temporal LobeRegistry: EpilepsyReclassifiedWhy we changed it
Registry
Epilepsy — the first condition term the registry derived for this study.
ClinicalTrials.gg
Epilepsy, Temporal Lobe
Why
  1. The study's title name Epilepsy, Temporal Lobe, a narrower term within Epilepsy.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Jul 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Recently, a possible subtype of temporal lobe epilepsy (TLE) has been proposed: this subtype presents ipsilateral amygdala enlargement (AE) without any other lesion. However, little is known about its clinical and psychiatric phenotype. The amygdala seems to play a major role in stress related disorders (including perception of stress). The hypothesis in this study is that patients with TLE-AE more frequently report emotional distress as a seizure-precipitating factor than any other epileptic patient.

Read the detailed description

TLE-AE could concern 16 to 64 % of the TLE with "negative" MRI (Beh et al., 2016).

TLE-AE patients may suffer from anxiety and depression (Lv et al, 2014). In clinical practice, it has been also identified an emotional vulnerability in these patients, as they report more frequently a high sensitivity to emotional distress than other epileptic patients. They also report a change in their affect intensity or a hyperemotivity, which appeared at the onset of their epilepsy. Lanteaume et al. have linked some TLE with an increased emotional vulnerability (Emo-TLE): these TLE patients reported stress factors precipitating their seizures. They found that the Emo-TLE group was characterized by an attentional bias toward threatening stimuli versus neutral stimuli, and that this bias was noticed neither in the TLE group without emotional vulnerability nor in healthy volunteers. But they did not study amygdala structure in each group.In the large database of the Toulouse University Hospital, screening was done to retrospectively collect TLE patients with AE identified on MRI. This large database has served to establish a reading grid in order to help the visual identification of an AE.The investigators propose to these patients them a series of validated scales to test:

  • The impact of emotional stress factors for precipitating seizures
  • The perception of stress (PSS-10).
  • Psychiatric comorbidities (anxiety, depression, post-traumatic stress disorder, emotional lability...).

The study also propose cognitive tasks to search for an attentional bias towards threatening stimuli (Emotional Stroop and modified probe test). After this, the study will assess their emotional subjective responses (valence, arousal, avoidance) through a task during which they are presented with short movies that elicit six different emotions. At the same time, the measure of the variations of their neurovegetative system in terms of blood pressure, heart rate variability and electrodermal skin conductance variability will be done.

For each TLE-AE patient, additional healthy controls will be matched (2 for testing the primary outcome, 3 for the secondary outcomes).

02

Conditions studied

  • Epilepsy

Keywords

  • amygdala enlargement
  • temporal lobe epilepsy
  • stress
  • attentional bias
  • anxiety
  • depression
  • PTSD
03

In context

Epilepsy, Temporal Lobe Reclassified

65 studies on the registry are indexed under Epilepsy, Temporal Lobe; 25 are open to participants now.

This study's planned enrollment of 120 is above the median of 30 across 41 interventional studies indexed under Epilepsy, Temporal Lobe.

Browse Epilepsy, Temporal Lobe studies →

Lead sponsor

University Hospital, Toulouse is the lead sponsor of 807 studies on the registry; 209 are open to participants now.

Compared within Epilepsy, Temporal Lobe, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For all epileptic patients: Age between 18 and 65. Epilepsy (TLE or not) followed by an epileptologist.
  • For TLE-AE: An AE identified on the MRI by an expert neuroradiologist. MRI must be less than one year.
  • For non AE epileptic patients: No AE reported in the MRI by an expert neuroradiologist.

Exclusion criteria

Exclusion Criteria:

  • Any mental disorder.
  • Any diabetes
  • Beta-blockers
  • Neuroleptics
  • Any neurologic diseases for the healthy volunteers.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    TLE-AE Group

    30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.

    Other: Measure of emotional stressors

  • Active comparator
    Non AE epileptic Group

    30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.

    Other: Measure of emotional stressors

  • Active comparator
    Extra-temporal epilepsy Group

    30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors and then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.

    Other: Measure of emotional stressors

  • Active comparator
    Healthy volunteers Group

    30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors

    Other: Measure of emotional stressors

Interventions

  • OtherMeasure of emotional stressors

    For the Epileptic Group * Rapid interrogation, completing the clinical data * A scale of impact of the precipitating factors of crises * An emotional Stroop * A task of detecting emotional targets against threatening information * A measure of the perception of emotions using film clips * A scale of measurement of perceived stress * The transfer of psychiatric scales For the healthy volunteers group : * A rapid interrogation, gathering the possible medical history, the level of studies, the manual laterality * An emotional Stroop * A task of detecting emotional targets against threatening information * A scale of measurement of perceived stress * A measure of the perception of emotions using film clips * A rapid neuropsychological assessment

06

What researchers measure

Primary outcomes

  1. Score on the scale of emotional seizure precipitant the outbreak

    It is a hetero-questionnaire, subjectively measuring the sensitivity of an epileptic patient to the stressors of daily life that may trigger or promote the onset of their seizures.

    Time frame: 30 minutes

Secondary outcomes

  1. Score of The Emotional Stroop tasks

    The score of the congruency index in the Emotional Stroop tasks : evaluate the attention bias towards threatening information

    Time frame: 30 minutes

  2. Score of The congruency index

    The score of the congruency index in the modified probe detection tasks : evaluate the attention bias towards threatening information

    Time frame: 30 minutes

  3. Score of the Scale measures during the movie tasks

    The score of scale (valence, arousal, avoidance) in the movie tasks : evaluate the emotional experience using film clips inducing emotion

    Time frame: 30 minutes

  4. Score of The Perceived Stress Scale 10

    The score of the Perceived Stress Scale 10 : evaluate the perception of stress

    Time frame: 30 minutes

  5. Score of The Tyrer's brief Scale for Anxiety (BAS)

    The score of the Tyrer's brief Scale for Anxiety (BAS) will evaluate the existence of an anxiety syndrome.This scale is validated, it is a hetero-questionnaire to evaluate anxiety, in 10 items, sides from 0 to 6.

    Time frame: 30 minutes

  6. Score of The Neurological Disorders Depression Inventory for Epilepsy (NDDI-E).

    The score of the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) : the existence of a depressive syndrome.

    Time frame: 30 minutes

  7. Score of The Affect intensity measure (AIM)

    The score of the Affect intensity measure (AIM) : the multidimensional assessment of thymic states (MAThyS) : evaluate the emotional lability

    Time frame: 30 minutes

  8. Score of The Clinical-administered PTSD Scale (CAPS)

    The clinical post-traumatic stress disorder scale (CAPS: Clinical-administered PTSD Scale) is the gold standard for diagnosing Post-Traumatic Stress Disorder (PTSD). To pass the entire questionnaire, it takes about sixty minutes. For the scoring list of milestones, it takes about 5 minutes. The CAPS is the only questionnaire that provides information on both the frequency and intensity of symptoms, with specific behavioral anchor points.

    Time frame: 30 minutes

  9. Score of The Post-Traumatic Checklist Scale (PCLS).

    The Post-Traumatic Checklist Scale (PCLS) is a simple self-questionnaire of about 10 minutes measuring the three main sub-syndromes of post-traumatic stress disorder: repetition (items 1 to 5), avoidance ( items 6 to 12) and neurovegetative hyperactivity (items 13 to 17). The scale is composed of 17 items, rated from 1 to 5. There is a cut-off at ≥ 45 to diagnose post-traumatic stress disorder. The validity of the French translation has been verified.

    Time frame: 30 minutes

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2018 (actual). Primary completion is estimated for Mar 2020, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2018
First posted
Mar 14, 2018
StartActual
Mar 8, 2018
Primary completionEst.
Mar 2020
CompletionEst.
Mar 2020
Last update
Jul 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03464370
Responsible party
Sponsor
First posted
Mar 14, 2018
Start date
Mar 8, 2018
Primary completion
Mar 2020 (estimated)
Completion
Mar 2020 (estimated)
Last update
Jul 20, 2018

Study contacts

Marie DENUELLE, MD
Contact
denuelle.m@chu-toulouse.fr
5 61 77 79 24 ext. 33
Isabelle Olivier, PhD
Contact
olivier.i@chu-toulouse.fr
5 61 77 70 51 ext. 33
Marie DENUELLE, MD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion